论文部分内容阅读
我们自1998年2月～1999年4月应用高效价乙肝免疫球蛋白(HBIG)、单磷酸阿糖腺苷(AraAMP)、胸腺肽及乙肝疫苗序贯注射治疗慢性乙肝42例取得了较好的疗效,报告如下。 1 材料与方法 1.1 病例选择:按照1995年全国病毒性肝炎会议制订的标准诊断和分度,选择HBsAg、HBeAg、HBcAb及HBV—DNA皆为阳性、肝功能异常的慢性乙型肝炎84例,随机分为治疗组42例和对照组42例。年龄24～54岁,平均年龄34.5岁。治疗组中度25例,轻度17例;对照组中度24例,轻度18例。两组在年龄构成、性别、病情分度等方面皆有可比性。所有病例在治疗前半年内未用抗病毒药物及
From February 1998 to April 1999, we obtained 42 cases of chronic hepatitis B with high titer HBIG, AraAMP, thymosin and hepatitis B vaccine , The report is as follows. 1 Materials and Methods 1.1 Case Selection: In accordance with the 1995 National Viral Hepatitis Conference to develop the standard diagnostic and indexing, select HBsAg, HBeAg, HBcAb and HBV-DNA were positive, 84 cases of chronic liver failure of liver function, randomized Divided into treatment group 42 cases and control group 42 cases. Aged 24 to 54 years old, with an average age of 34.5 years old. The treatment group was moderate in 25 cases and mild in 17 cases. The control group was moderate in 24 cases and mild in 18 cases. The two groups are comparable in terms of age, sex, and degree of illness. All cases in the first half of treatment without antiviral drugs and